Mukthinuthalapati Mathrusri Annapurna* and Kakara Sri Lakshmi Sai Sriya

GITAM School of Pharmacy, GITAM (Deemed to be) University, Visakhapatnam, Andhra Pradesh-530045, India

*Corresponding Author: Mukthinuthalapati Mathrusri Annapurna, Department of Pharmaceutical Analysis, GITAM School of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, India.

Received: November 28, 2025; Published: December 31, 2025

Abstract

Vildagliptin is used to manage type II diabetes mellitus. It inhibits the inactivation of glucagon-like peptide-1 and glucose-dependent insulinotropic poly peptide by dipeptidyl peptidase-4 allowing glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas. Vildagliptin was approved by the European Medicines Agency in 2007. In the present study the authors have summarised the analytical methods so far developed for the estimation of Vildagliptin in the literature.

Keywords: Vildagliptin; Type II Diabetes Mellitus

References

1. Balas B., et al. “The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients”. The Journal of Clinical Endocrinology and Metabolism 4 (2007): 1249-1255.
2. Croxtall JD and Keam SJ. “Vildagliptin: A review of its use in the management of type 2 diabetes mellitus”. Drugs16 (2008): 2387-2409.
3. He YL. “Clinical pharmacokinetics and pharmacodynamics of Vildagliptin”. Clinical Pharmacokinetics3 (2012): 147-162.
4. Ramakrishna M., et al. “Development of simple UV-spectrophotometric method for the estimation of Vildagliptin in bulk and its formulation”. International Journal of Pharmaceutics and Drug Analysis1 (2024): 29-36.
5. Safila Naveed., et al. “Method development and validation of Vildagliptin using UV spectrophotometer”. International Journal of Pharma Sciences and Research10 (2014): 714-717.
6. Beena Kumari., et al. “Analytical method development and validation of UV-visible spectrophotometric method for the estimation of Vildagliptin in gastric medium”. Drug Research9 (2020): 417-423.
7. Subhadip C., et al. “A new second-derivative spectrophotometric method for the determination of Vildagliptin in pharmaceutical dosage form”. International Journal of Research in Pharmaceutical Sciences4 (2021): 2610-2614.
8. Sheetal Vishnudas Mane., et al. “Development of UV-visible spectrophotometric method for the estimation of Vildagliptin in different medium”. Journal of Pharmaceutical and Biological Sciences2 (2023): 83-87.
9. Razia Sultana., et al. “Development and validation of stability indicating assay method of Vildagliptin in bulk and tablet dosage form by RP-HPLC”. International Journal of Pharmacy and Life Sciences4 (2013): 2530-2534.
10. Darwish M. “Efficient RP-HPLC method for the detection and quantification of Vildagliptin in bulk and pharmaceutical formulations”. Eurasian Journal of Chemical, Medicinal, Petroleum Research3 (2024): 1064-1074.
11. Kumaraswamy G., et al. “A validated RP-HPLC method for estimation of Vildagliptin in bulk and tablet dosage forms”. World Journal of Pharmacy and Pharmaceutical Sciences8 (2022): 1720-1728.
12. Pragati Ranjan S., et al. “Development and validation of a RP-HPLC method for the assay of Vildagliptin”. World Journal of Pharmacy and Pharmaceutical Sciences2 (2014): 2303-2310.
13. Thangabalan B., et al. “RP-HPLC determination of Vildagliptin in pure and in tablet formulation”. Journal of Pharmacy Research”. 1 (2013): 113-116.
14. Cristiane de Andrade., et al. “Validation of LC-MS/MS method applied to evaluation of free tissue concentrations of Vildagliptin in diabetic rats by micro dialysis”. Biomedical Chromatography12 (2014): 1722-1727.
15. Santosh T., et al. “Addressing stability issues of vildagliptin: Method optimization and validation for accurate analysis in human plasma”. Biomedical Chromatography11 (2024): e5991.
16. Sakthimanigandan K., et al. “Liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the determination of Vildagliptin in rat plasma”. Acta Chromatographica2 (2015): 295-307.
17. Vipin Kumar., et al. “N-Nitroso Vildagliptin, A new N-Nitrosamine drug substance related impurity (NDSRI) of Vildagliptin an antidiabetic drug: Synthesis, characterization and development of sensitive LC–MS/MS method”. Chromatographia10 (2025): 791-799.
18. Ayushman Tiwari., et al. “Bioanalytical method development and validation of Vildagliptin in rat plasma using LCMS/MS method”. Journal of Advanced Scientific Research3 (2019): 22-29.

Citation

Citation: Mukthinuthalapati Mathrusri Annapurna., et al. “Analytical Techniques for the Assay of Vildagliptin: A Review"". Acta Scientific Pharmaceutical Sciences 10.1 (2026): 71-73.

Copyright

Copyright: © 2026 Mukthinuthalapati Mathrusri Annapurna., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.